Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta-analysis

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Abstract: Integrin-beta 1 (ITGB1) is aberrantly overexpressed or downregulated in solid cancers; however, its prognostic value remains controversial. Therefore, we conducted a meta-analysis to explore whether ITGB1 expression is correlated with overall survival (OS) and the clinicopathological characteristics of patients with solid cancers. We systematically searched the PubMed, Embase, and Web of Science databases for eligible studies published up to June 1, 2017. In total, 22 studies involving 3,666 patients were included. A sensitivity analysis was performed to assess the validity and reliability of the pooled OS. Among the 22 studies, 7 focused on lung cancer, 3 focused on colorectal cancer, 6 focused on breast cancer, 3 involved melanoma, and 3 involved pancreatic cancer. The pooled results showed that high ITGB1 expression was significantly associated with worse OS in lung cancer (pooled hazard ratio [HR]=1.78, 95% CI: 1.19–2.65, p<0.05) and breast cancer (pooled HR=1.88, 95% CI: 1.46–2.42, p<0.01). In addition, a significant association was observed between high ITGB1 expression and disease-free survival in breast cancer (pooled HR=1.63, 95% CI: 1.17–2.25, p<0.001) and pancreatic cancer (pooled HR=2.49, 95% CI: 1.35–4.61, p<0.001). However, high ITGB1 expression was not related to OS in colorectal cancer, pancreatic cancer, or melanoma. The pooled HRs used to evaluate the prognostic value of increased ITGB1 expression in lung cancer, breast cancer, and pancreatic cancer were not significantly altered, which indicates that the pooled results were robust. The results of this study indicate that the prognostic value of decreased ITGB1 expression varies among solid cancers.

Keywords: ITGB1, solid cancer, prognosis, meta-analysis

Introduction
Cancer is a major cause of death worldwide; in 2012, 14.1 million new cancer cases and 8.2 million cancer-related deaths were reported across the world. Currently, several therapeutic strategies, including radical operation, chemotherapy, and radiotherapy, are available for primary solid tumors and metastatic cancers. Nevertheless, the therapeutic response differs significantly in patients. Therefore, it is imperative to develop effective and clinically applicable biomarkers to accurately evaluate the therapeutic effect and prognosis of patients with cancer.

Integrins are a family of transmembrane receptors that generally consist of non-covalently linked alpha and beta subunits. Integrins have a variety of functions in cell adhesion and contact, and anchorage-dependent cell survival, and regulate various cellular processes including tissue healing, hemostasis, immune response, cell differentiation, division, growth, recognition, and migration. Recent evidence suggests that integrins are involved in many processes associated with tumor cell adhesion to the extracellular matrix, including migration, invasion, and metastasis. Moreover, previous studies have shown that integrins play an important role in the regulation of
tumor angiogenesis. Additional investigations indicate that integrins can interact with tyrosine kinase receptors, such as epidermal growth factor receptor and vascular epidermal growth factor receptor, to promote cancer cell proliferation, survival, and differentiation.

Integrin-beta 1 (ITGB1), also known as CD29, is a member of the integrin family and is composed of alpha and beta transmembrane subunits that form at least 24 distinct heterodimeric receptors. The role of ITGB1 in malignant phenotypes of cancers has gained a lot of attention. Previous studies have suggested that ITGB1 is the predominantly expressed integrin in normal and tumor cells and controls various developmental processes including angiogenesis, tumor progression, and metastasis. Other studies have also shown that, in many cancer types, ITGB1 may induce resistance to radiotherapies, chemotherapies, and targeted therapies. On the basis of these findings, ITGB1 has been studied extensively in terms of the biology of solid tumors, and its aberrant expression at the protein or RNA level has been shown to correlate with poor prognosis in several types of cancer, including lung cancer, gastric cancer, breast cancer, prostate cancer, pancreatic carcinoma, and colorectal cancer, making it a potential target for antitumor therapies. Nevertheless, the prognostic significance of ITGB1 expression in patients with cancer remains inconsistent. For instance, some studies have reported that decreased ITGB1 protein expression is associated with more aggressive breast cancer types, but the conclusion was different in other studies. Some studies could not verify a significant correlation between ITGB1 protein expression and survival of patients with breast carcinoma.

Thus far, no meta-analyses of studies focusing on the investigation of the prognostic and clinicopathological significance of ITGB1 in patients with solid tumors have been performed. Furthermore, conclusions made from most studies published so far are limited by small sample sizes. Therefore, we conducted a meta-analysis to estimate the prognostic and clinicopathological value of ITGB1 in patients with solid cancers.

Materials and methods

Literature search strategy and study selection
We searched the PubMed, Embase, and Web of Science databases to identify all relevant studies that assessed the association between ITGB1 expression and survival outcome in patients with solid cancers published up to June 1, 2017. The search terms included the following terms: (“ITGB1” or “Integrin β1”), (“cancer” or “tumor” or “malignancy” or “carcinoma”), and (“prognos*”). The publication language was limited to English.

Studies were included in the analysis if they met the following inclusion criteria: 1) the studies investigated the association between ITGB1 and overall survival (OS) or disease-free survival (DFS) among patients with primary solid cancers or metastasis; 2) relevant clinicopathological characteristics were presented; 3) tumor tissues from patients with solid cancers were used for the determination of ITGB1 expression; 4) patients were grouped into high and low expression groups according to the ITGB1 protein or RNA level; and 5) sufficient information and data were available to calculate hazard ratios (HRs) with 95% CIs. The exclusion criteria were as follows: 1) studies that were published as reviews, abstracts, case reports, letters, or comments, as well as duplicate studies; 2) studies in which human cell lines or animals were used; and 3) studies that failed to provide the HRs with 95% CIs or Kaplan–Meier survival curves used to calculate the OS and DFS.

Data extraction and quality assessment
All the candidate publications were reviewed, and the data were extracted by 2 independent investigators. The third investigator was responsible for reconciling disagreements when the results were controversial. The following information was extracted: cancer type, first author’s name, publication year, region, number of patients, patients’ ages, test method, rate of high ITGB1 expression, clinical and pathological features, follow-up duration, OS, and DFS. If the results of both the univariate and multivariate analyses were provided in the studies, only the latter were extracted owing to their higher accuracy, since multivariate analyses account for confounding factors. Moreover, the selection of participants, comparability, and ascertainment of outcomes were assessed. The study quality was assessed using the standard Newcastle–Ottawa Scale, which ranges from 0 (minimum) to 9 (maximum). If the final score of a study was higher, it indicated that the study’s methodological quality was better. A study with a score of 6 or higher was defined as “high-quality.”

Statistical analysis
The meta-analysis was performed using Stata SE12.0 (Stata Corp., College Station, TX, USA). HRs and 95% CIs were used to assess the prognostic value of ITGB1, and odds ratios (ORs) with 95% CIs were used to evaluate the association between ITGB1 expression and...
Results

Study selection and study characteristics

A total of 284 articles were primarily identified, 70 of which were from PubMed, 123 from Embase, and 91 from Web of Science. After duplicate publications were removed and the remaining abstracts and full texts meticulously reviewed, 22 publications were finally determined to be eligible for the present pooled analysis. The inclusion of the publications in the analysis was based on the selection criteria mentioned above. The detailed selection process is shown in Figure 1.

The pooled result revealed that high ITGB1 expression was significantly associated with worse OS in patients with lung cancer (pooled HR = 1.78, 95% CI: 1.19–2.65, p < 0.05) (Figure 2) and breast cancer (pooled HR = 1.88, 95% CI: 1.46–2.42, p < 0.01) (Figure 3). In addition, no significant
| Cancer type                      | First author (year) | Region               | Time of recruitment | No of patients | Age (years), median (range) | Test method | Rate of high ITGB1 expression (%) | Survival outcomes (HR, 95% CI), H/L | Follow-up (months), median | NOS score |
|----------------------------------|---------------------|----------------------|---------------------|----------------|-----------------------------|-------------|---------------------------------|-------------------------------------|-------------------------------|-----------|
| Small cell lung cancer           | Chang et al (2012)  | Korea                | 2000–2008           | 112            | 66 (42–88)                  | IHC         | 57.1                            | OS: 0.98 (0.66–1.45)              | 61               | 7         |
| Non-small cell lung cancer       | Dingemans et al (2010) | the Netherlands       | 1995–1999           | 68             | 69.1 (44.5–90.2)            | Real-time qPCR | NR                              | OS: 2.11 (1.21–3.69); DFS: 1.53 (0.87–2.70) | 93               | 6         |
| Small cell lung cancer           | Lawson et al (2010) | UK                   | 1998–2005           | 151            | 67.3 (9.93)                 | IHC         | 70.2                            | OS: 1.67 (1.09–2.56)              | 72               | 7         |
| Non-small cell lung cancer       | Liang et al (2017)  | China                | NR                  | 134            | NR                          | IHC         | NR                              | OS: 1.56 (0.96–2.53)              | NR               | 5         |
| Non-small cell lung cancer       | Okamura et al (2007) | Japan                | 1997–2000           | 118            | 65 (41–79)                  | IHC         | 66.9                            | OS: 1.41 (0.80–2.49)              | 71.0             | 7         |
| Lung adenocarcinoma              | Zhang et al (2017)  | China                | 2004–2006           | 108            | NR                          | IHC         | 32.4                            | RFS: 6.592 (4.106–10.584); OS: 6.183 (3.851–9.929) | 60               | 7         |
| Non-small cell lung cancer       | Zheng et al (2016)  | China                | NR                  | 959            | 67 (38–90)                  | TCGA RNASeq database | NR                              | OS: 1.31 (1.10–1.55)              | NR               | 5         |
| Colorectal cancer                | Langan et al (2012) | USA                  | NA                  | 30             | 56 (35–76)                  | IHC         | NR                              | OS: 0.28 (0.06–1.27)              | 113              | 6         |
| Colorectal cancer                | Liu et al (2015)    | China                | 2001–2013           | 582            | NR                          | IHC         | 52.6                            | OS: 1.537 (1.147–2.059)            | 100              | 6         |
| Colorectal liver metastases      | Vassos et al (2014) | Germany              | 1995–2010           | 81             | NR                          | IHC         | 45.7                            | OS: 1.23 (0.44–3.43); DFS: 0.95 (0.44–2.01) | 55               | 6         |
| HER-2-positive metastatic breast cancer | Lesniak et al (2009) | Canada              | 1998–2002           | 78             | NR                          | IHC         | 29.5                            | OS: 2.82 (1.52–4.24)              | 28               | 6         |
| Breast cancer                    | McSherry et al (2009) | Ireland             | 1988–1992           | 272            | NR                          | IHC         | NR                              | OS: 1.16 (0.62–2.19)              | NR               | 6         |
| Breast cancer                    | Petricevic et al (2012) | Croatia            | 2002–2003           | 133            | NR                          | IHC         | 36.4                            | NR                                  | 60               | 7         |
| Breast cancer                    | dos Santos et al (2012) | Brazil             | 1994–2010           | 225            | 55                          | IHC         | 32.9                            | DSS: 2.51 (1.24–3.7); DFS: 1.38 (0.86–2.23); MFS: 1.94 (1.07–3.52) | NR               | 7         |
| Breast cancer                    | Yao et al (2007)    | USA                  | 1974–1999           | 149            | NR                          | IHC         | 10.1                            | OS: 1.73 (1.22–2.44); DFS: 1.88 (1.20–2.95) | 60               | 7         |
| Breast cancer                    | Yin et al (2016)    | China                | NR                  | 67             | 51                          | IHC         | 43.3                            | OS: 2.772 (1.011–7.600)            | NR               | 6         |
| Melanoma                         | Hieken et al (1999) | USA                  | 1976–1995           | 111            | 53                          | IHC         | 32.4                            | OS: 3.10 (0.9–10.73)              | 105              | 7         |
| Melanoma                         | Nikkola et al (2004) | Finland             | 1989–1995           | 55             | 47                          | IHC         | 10.7                            | DFS: 3.36 (2.03–5.54)             | NR               | 6         |
Increased integrin-beta 1 expression in solid cancers

An increased integrin-beta 1 expression in solid cancers was found between high ITGB1 expression and OS in colorectal cancer (pooled HR = 1.06, 95% CI: 0.48–2.32, p < 0.001) (Figure 4), pancreatic cancer (pooled HR = 1.41, 95% CI: 0.76–2.61, p < 0.0001) (Figure 5), or melanoma (pooled HR = 0.79, 95% CI: 0.06–11.08, p = 0.01) (Figure 6).

High ITGB1 expression and DFS in solid cancers

The pooled result revealed that high ITGB1 expression was significantly associated with worse DFS in patients with breast cancer (pooled HR = 1.63, 95% CI: 1.17–2.25, p < 0.001) (Figure 7) and pancreatic cancer (pooled HR = 2.49, 95% CI: 1.35–4.61, p < 0.001) (Figure 8). In addition, no significant association was found between high ITGB1 expression and DFS in lung cancer (pooled HR = 3.20, 95% CI: 0.77–13.40, p < 0.01) (Figure 9) or melanoma (pooled HR = 0.88, 95% CI: 0.06–13.25, p = 0.05) (Figure 10).

High ITGB1 expression and clinicopathological factors in lung cancer

Considering that the biology, pathology, clinical courses, and treatments vary enormously among different types of solid cancers, we assessed the associations between high ITGB1 expression and clinicopathological characteristics in lung cancer, breast cancer, and pancreatic cancer. However, high expression of ITGB1 was not evaluated in colorectal cancer and melanoma owing to limited data on the clinicopathological features. Six studies reported a relationship between high ITGB1 expression and clinicopathological factors in lung cancer, including 2 studies that investigated tumor differentiation, N stage, T stage, and age (Table 3). Except for T stage ($I^2 = 0, p = 0.50$) and age ($I^2 = 5\%, p = 0.305$), significant heterogeneity was observed between high ITGB1 expression and tumor differentiation ($I^2 = 85\%, p = 0.01$) and N stage ($I^2 = 74.7\% p = 0.047$). The pooled analysis showed no significant association between high ITGB1 expression and tumor differentiation (OR = 0.69, 95% CI: 0.10–4.98, p = 0.712), N stage (OR = 0.40, 95% CI: 0.16–1.01, p = 0.053), or age (OR = 0.98, 95% CI: 0.70–1.37, p = 0.921) (Table 3), while high ITGB1 expression showed a strong association with worse T stage (OR = 0.64, 95% CI: 0.41–0.98, p = 0.041) (Table 3).

High ITGB1 expression and clinicopathological factors in breast cancer

A total of 6 studies identified an association between ITGB1 expression and clinicopathological factors in breast cancer.
No significant heterogeneity was identified between high ITGB1 expression and N stage ($I^2=2\%$, $p=0.36$), tumor grade ($I^2=0$, $p=0.636$), T stage ($I^2=0$, $p=0.639$), metastasis ($I^2=0$, $p=0.357$), estrogen receptor (ER) ($I^2=14.8\%$, $p=0.279$), progesterone receptor (PR) ($I^2=43.6\%$, $p=0.183$), or human epidermal growth factor receptor (HER) ($I^2=29.9\%$, $p=0.232$); therefore, a fixed-effects model was used for the analysis (Table 3). The pooled analysis revealed no
Increased integrin-beta 1 expression in solid cancers

Figure 3 Results of pooled hazard ratios of overall survival of patients with high integrin-beta 1 (ITGB1) expression level in breast cancer. 
Abbreviation: HR, hazard ratio.

Figure 4 Results of pooled hazard ratios of overall survival of patients with high integrin-beta 1 (ITGB1) expression level in colorectal cancer. 
Note: Weights are from random effects analysis. 
Abbreviation: HR, hazard ratio.

Figure 5 Results of pooled hazard ratios of overall survival of patients with high integrin-beta 1 (ITGB1) expression level in pancreatic cancer. 
Note: Weights are from random effects analysis. 
Abbreviation: HR, hazard ratio.
Figure 6 Results of pooled hazard ratios of overall survival of patients with high integrin-beta 1 (ITGB1) expression level in melanoma.

Note: Weights are from random effects analysis.

Abbreviation: HR, hazard ratio.

Figure 7 Results of pooled hazard ratios of disease-free survival of patients with high integrin-beta 1 (ITGB1) expression level in breast cancer.

Abbreviation: HR, hazard ratio.

Figure 8 Results of pooled hazard ratios of disease-free survival of patients with high integrin-beta 1 (ITGB1) expression level in lung cancer.

Note: Weights are from random effects analysis.

Abbreviation: HR, hazard ratio.
significant relationship between increased ITGB1 expression and N stage (OR=0.79, 95% CI: 0.52–1.19, \( p=0.262 \)), tumor grade (OR=1.20, 95% CI: 0.74–1.94, \( p=0.462 \)), T stage (OR=0.78, 95% CI: 0.51–1.19, \( p=0.25 \)), ER (OR=1.45, 95% CI: 0.90–2.35, \( p=0.462 \)), PR (OR=1.15, 95% CI: 0.74–1.80, \( p=0.527 \)), or HER (OR=1.70, 95% CI: 0.98–2.93, \( p=0.057 \)), while high ITGB1 expression demonstrated a strong association with metastasis (OR=1.99, 95% CI: 1.18–3.38, \( p=0.010 \)) (Table 3).

### ITGB1 expression and clinicopathological factors in pancreatic cancer

Only 2 studies reported a relationship between ITGB1 expression and age in pancreatic cancer. No significant heterogeneity was detected in the studies regarding age (\( I^2 = 0 \), \( p=0.459 \)); therefore, a fixed-effects model was applied. The pooled results showed that high ITGB1 expression was not significantly correlated with age (OR=1.35, 95% CI: 0.65–2.80, \( p=0.417 \)) (Table 3).

### Sensitivity analysis

Sensitivity analyses were performed to evaluate the stability of the pooled results for OS in lung cancer (Figure 11), breast cancer (Figure 12), and pancreatic cancer (Figure 13). The results of the sensitivity analyses showed that the pooled HRs for OS did not change substantially, which indicates that the conclusions from our meta-analysis were relatively reliable.

### Publication bias

Begg’s and Egger’s tests were used to assess publication bias in our meta-analysis. The results revealed that there was no significant bias in the pooled HRs for OS in lung cancer (Begg’s test, \( z=1.05, p=0.293 \); Egger’s test, \( t\)-bias=1.10,

---

**Figure 9** Results of pooled hazard ratios of disease-free survival of patients with high integrin-beta 1 (ITGB1) expression level in pancreatic cancer.

**Note:** Weights are from random effects analysis.

**Abbreviation:** HR, hazard ratio.

**Figure 10** Results of pooled hazard ratios of disease-free survival of patients with high integrin-beta 1 (ITGB1) expression level in melanoma.

**Note:** Weights are from random effects analysis.

**Abbreviation:** HR, hazard ratio.
Table 3  Meta-analysis results of the associations of integrin-beta 1 with clinicopathological parameters

| Clinicopathological parameter | No of studies | Reference no | OR (95% CI) | p-value | Heterogeneity test |
|------------------------------|---------------|--------------|-------------|---------|-------------------|
|                              |               |              |             |         | I² (%) p-value     |
| **Lung cancer**              |               |              |             |         |                   |
| Tumor differentiation (moderate–well vs poor) | 2             | 637          | 0.69 (0.10–4.98) | 0.712   | 85.0 0.010        |
| N stage (N0 vs N+)           | 2             | 663          | 0.40 (0.160–1.01) | 0.053   | 74.7 0.047        |
| T stage (T1–2 vs T3–4)       | 2             | 663          | 0.64 (0.41–0.98)  | 0.041   | 0.0   0.5          |
| Age (<60 vs ≥60 years)       | 2             | 665          | 0.98 (0.70–1.37)  | 0.921   | 5.0   0.305        |
| **Breast cancer**            |               |              |             |         |                   |
| N stage (N0 vs N+)           | 3             | 399          | 0.79 (0.52–1.19)  | 0.262   | 2.0   0.360        |
| Tumor grade (I–II vs III–IV) | 3             | 424          | 1.20 (0.74–1.94)  | 0.462   | 0.0   0.636        |
| T stage (T1 vs T2–3)         | 3             | 424          | 0.78 (0.51–1.19)  | 0.250   | 0.0   0.639        |
| Metastasis (yes vs no)       | 2             | 292          | 1.99 (1.18–3.38)  | 0.010   | 0.0   0.357        |
| ER (+ vs –)                  | 2             | 352          | 1.45 (0.90–2.35)  | 0.126   | 14.8 0.279        |
| PR (+ vs –)                  | 2             | 352          | 1.15 (0.74–1.80)  | 0.527   | 43.6 0.183        |
| HER (+ vs –)                 | 2             | 357          | 1.70 (0.98–2.93)  | 0.057   | 29.9 0.232        |
| **Pancreatic cancer**        |               |              |             |         |                   |
| Age (<60 vs ≥60 years)       | 2             | 117          | 1.35 (0.65–2.80)  | 0.417   | 0.0   0.459        |

**Abbreviations:** ER, estrogen receptor; PR, progesterone receptor; HER, human epidermal growth factor receptor; OR, odds ratio.

Discussion

Studies have shown conflicting results regarding the role of ITGB1 in the carcinogenesis of solid cancers;\(^{28–30}\) therefore, its prognostic value in patients with solid cancers is also inconsistent and remains unknown. Although several previous studies reported that ITGB1 could induce resistance to chemotherapy and radiation in several human cancers,\(^{53,54}\) the impact of increased ITGB1 expression on the prognosis of patients with solid cancers has not been fully explored. Hence, we combined 22 publications involving 3,666 patients to perform the first meta-analysis that evaluated the association between ITGB1 and OS and DFS in patients with solid cancers. In addition, we explored the relationship between low ITGB1 expression and the clinicopathological features of solid cancers.

The pooled results of the meta-analysis revealed that high ITGB1 expression was significantly associated with worse OS in lung cancer and breast cancer. Moreover, the results showed that high ITGB1 expression was not related to OS in colorectal cancer, pancreatic cancer, or melanoma. In addition, the pooled result revealed that high ITGB1 expression...
was significantly associated with worse DFS in breast cancer and pancreatic cancer. The sensitivity analyses demonstrated that the pooled HRs used to evaluate the prognostic value of increased ITGB1 expression in lung cancer, breast cancer, and pancreatic cancer were not significantly altered, which indicates that the pooled results were robust. Considering the above findings, we believe that the prognostic value of increased ITGB1 expression varies according to cancer type in patients with solid cancer.

In addition, we investigated the relationship between ITGB1 expression and clinicopathological characteristics to further validate the pooled results of the association between OS and ITGB1 expression. Increased ITGB1 expression was significantly associated with worse T stage in lung cancer. However, the results showed no significant association between high ITGB1 expression and tumor differentiation and N stage. In addition, high ITGB1 expression strongly correlated with metastasis in breast cancer. Similarly, the results revealed no significant relationship between increased ITGB1 expression and N stage, tumor grade, T stage, ER, PR, or HER in breast cancer. This result should be interpreted with caution. On the one hand, the prognostic value and association between ITGB1 expression and the clinicopathological features of lung cancer and breast cancer may vary with the subtype of cancer. On the other hand, the included sample size was relatively small, which may have led to statistical bias. Previous studies have verified that ITGB1 overexpression promoted lymph-node metastasis in lung cancer. Bredin et al found that ITGB1 was involved in lung cancer cell migration in vitro, and upregulation of ITGB1 was identified as an important factor for gefitinib resistance in a lung cancer cell line. In addition, the overexpression of ITGB1 was found to promote the invasion and metastasis of lung cancer. In addition, Klahan et al reported that knockdown of ITGB1 inhibited the migration and invasion of breast cancer cells. Therefore, to date, the published literature supports the notion that the effects of ITGB1 on the biological functions of solid cancer cells vary according to the type of malignant cells, which is consistent with the results of our meta-analysis.

Our study had several significant limitations; therefore, the results should be interpreted with caution. First, only English language publications were included in this meta-analysis, which may have introduced publication bias. Second, only 3 studies on colorectal cancer, melanoma, and pancreatic cancer were included; therefore, it was difficult to accurately assess the association between ITGB1 expression and survival in these 3 cancer types. Third, although the HRs with 95% CIs in most of the included studies were calculated via a multivariate analysis, the variables added into the Cox proportional hazard models varied across studies. Fourth, all the included studies failed to carefully describe the location of the ITGB1 expression in the tumor specimens; therefore, further studies should be performed to determine whether the increased ITGB1 expression appears at cell-matrix attachment sites or in the epithelial or stromal regions. Fifth, this meta-analysis did not explore the correlation between increased ITGB1 expression and ER+/HER2+ and triple-negative breast cancers owing to the unavailability of data. Sixth, our study failed to determine whether high ITGB1 expression was associated with the type of metastasis. Last but not least, the sample size and the number of the included studies for the pooled estimate of clinicopathological parameters were rather small, which may have affected the reliability of the pooled ORs for the associations between high ITGB1 expression and clinicopathological parameters.

**Conclusion**

The prognostic significance of increased ITGB1 expression varies according to cancer type. Overall, high ITGB1 expression was significantly associated with a worse OS in lung cancer and breast cancer and a worse DFS in breast cancer and pancreatic cancer. However, high ITGB1 expression was not related to OS in colorectal cancer, pancreatic cancer, or melanoma. Further high-quality clinical studies that overcome the aforementioned limitations need to be performed to validate the prognostic value of increased ITGB1 expression in patients with solid cancer.
Disclosure
The authors report no conflicts of interest in this work.

References
1. Torre LA, Bray F, Siegel RL, et al. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(2):15–29.
2. Hynes RO. Integrins: the extracellular matrix- and cell-surface receptors for cell adhesion. J Cell Biol. 2000;150(2):F89–F96.
3. Chung J, Kim TH. Integrin-dependent translational control: implication in cancer progression. Microsc Res Tech. 2008;71(5):380–386.
4. Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signaling trends. Nat Cell Biol. 2002;4(4):E65–E68.
5. Naci D, Vuori K, Aoudjit F. Alpha2beta1 integrin in cancer development and chemoresistance. Semin Cancer Biol. 2015;35:145–153.
6. Scales TM, Parsons M. Spatial and temporal regulation of integrin signaling during cell migration. Curr Opin Cell Biol. 2011;23(5):562–568.
7. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–687.
8. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresi DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270(5241):1500–1502.
9. Brooks PC, Clark RA, Cheresi DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264(518):569–571.
10. Helgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta. 2007;1775(1):163–180.
11. Rintoul RC, Sethi T. The role of extracellular matrix in small-cell lung cancer. J Cell Sci. 2002;115(Pt 12):2271–2282.
12. Kenny PA, Lee GY, Myers CA, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Med. 2001;7(1):46–58.
13. Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA. Ligand-independent EGFR signaling. Cancer. 2015;150(2):F89–F96.
14. Fujita S, Watanabe M, Kubota T, Teramoto T, Kitajima M. Alteration of expression in integrin beta 1-subunit correlates with invasion and independent EGFR signaling. Cancer Res. 2007;67(2):659–664.
15. Hu C, Ni Z, Li BS, et al. hTERT promotes the invasion of gastric cancer cells. Clin Cancer Res. 2010;16(11):260–268.
16. Yao ES, Zhang H, Chen YY, et al. Increased beta 1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007;67(2):659–664.
17. Petricevic B, Vrbanec D, Jakic-Razumovic J, et al. Expression of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med Oncol. 2012;29(2):486-494.
18. Lanzafame S, Emmanuele C, Torrisi A. Correlation of alpha2beta1 integrin expression with histological type and hormonal receptor status in breast carcinomas. Pathol Res Pract. 1996;192(10):1031–1038.
19. Pontes-Júnior J, Reis ST, Bernardes FS, et al. Correlation between beta1 integrin expression and prognosis in clinically localized prostate cancer. Int Braz J Urol. 2013;39(3):335–342; discussion 343.
20. Böttger TC, Maschek H, Lobo M, Gottwald RC, Brenner WA, Junginger H. Prognostic value of immunohistochemical expression of beta1-integrin in pancreatic cancer. Oncology. 1999;56(4):308–313.
21. Zhou G, Chiu D, Qiu D, et al. Expression of CD44v6 and integrin-b1 for the prognosis evaluation of pancreatic cancer patients after curative surgery. Diaag Pathol. 2013;8:146.
22. Vassos N, Rau T, Merkel S, et al. Prognostic value of beta1 integrin expression in colorectal liver metastases. Int J Clin Exp Pathol. 2014;7(1):288–300.
23. Liu QZ, Gao XH, Chang WJ, et al. Expression of ITGB1 predicts prognosis in colorectal cancer: a large prospective study based on tissue microarray. Int J Clin Exp Pathol. 2015;8(10):12802–12810.
24. Gonzalez MA, Pinder SE, Wencyk PM, et al. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta-gamma-catenins, and alpha2- and beta1-integrins in invasive breast cancer. J Pathol. 1999;187(5):523–529.
25. Klahan S, Huang WC, Chang CM, et al. Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer. PharmacoRes. 2016;104:31–37.
26. Berry MG, Gui GP, Wells CA, Carpenter R. Integrin expression and survival in human breast cancer. Eur J Surg Oncol. 2004;30(5):484–489.
27. Lawson MH, Cummings NM, Rassl DM, et al. Bcl-2 and beta1 integrin predict survival in a tissue microarray of small cell lung cancer. Br J Cancer. 2010;103(11):1710–1715.
28. Liang Z, Kong R, He Z, et al. High expression of miR-493-5p positively correlates with clinical prognosis of non small cell lung cancer by targeting onecogene ITGB1. Oncotarget. 2017;8(29):47389–47399.
29. Okamura M, Yamaji S, Nagashima Y, et al. Prognostic value of integrin-b1-ILK-pAkt signaling pathway in non-small cell lung cancer. Hum Pathol. 2007;38(1):1081–1091.
30. Zhang PF, Zeng GQ, Yi LZ, et al. Identification of integrin b1 as a prognostic biomarker for human lung adenocarcinoma using 2D-LC-MS/MS combined with iTRAQ technology. Oncol Rep. 2013;30(1):341–349.
31. Langan RC, Mullinax JE, Ray S, et al. A pilot study assessing the potential role of non-CD133 colorectal cancer stem cells as biomarkers. J Cancer. 2012;3:231–240.
32. Lesnick DA, Xu Y, Deschenes J, et al. Bcl-1 integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 2009;69(22):8620–8628.
33. McSherry EA, McGee SF, Jirstrom K, et al. JAM-A expression positively correlates with poor prognosis in breast cancer patients. Int J Cancer. 2009;125(6):1343–1351.
46. dos Santos PB, Zanetti JS, Ribeiro-Silva A, Beltrão EI. Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study. Diagn Pathol. 2012;7:104.

47. Yin HL, Wu CC, Lin CH, et al. β1 Integrin as a prognostic and predictive marker in triple-negative breast cancer. Int J Mol Sci. 2016;17(9):1432.

48. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer. 1999;85(2):375–382.

49. Nikkola J, Vihinen P, Vlaykova T, Hakka-Kemppinen M, Heino J, Pyrhonen S. Integrin chains beta 1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 2004;14(1):29–37.

50. Vihinen P, Nikkola J, Vlaykova T, et al. Prognostic value of beta 1 integrin expression in metastatic melanoma. Melanoma Res. 2000;10(3):243–251.

51. Sawai H, Okada Y, Funahashi H, et al. Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene. 2006;25(23):3237–3246.

52. Yang D, Shi J, Fu H, et al. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. Tumour Biol. 2016;37(9):12315–12327.

53. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001;20(36):4995–5004.

54. Nam JM, Chung Y, Hsu HC, Park CC. β1 Integrin targeting to enhance radiation therapy. Int J Radiat Biol. 2009;85(11):923–928.

55. Han JY, Kim HS, Lee SH, Park WS, Lee JY, Yoo NJ. Immunohistochemical expression of integrins and extracellular matrix proteins in non-small cell lung cancer: correlation with lymph node metastasis. Lung Cancer. 2003;41(1):65–70.

56. Bredin CG, Sundqvist KG, Hauzenberger D, Klominek J. Integrin dependent migration of lung cancer cells to extracellular matrix components. Eur Respir J. 1998;11(2):400–407.

57. Ju L, Zhou C, Li W, Yan L. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem. 2010;111(6):1565–1574.